Summary
- Profile Type
- Business Offer
- POD Reference
- BOGB20240930005
- Term of Validity
- 30 September 2024 - 30 September 2025
- Company's Country
- United Kingdom
- Type of partnership
- Commercial agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- The UK company specialises in anti-inflammatory live biotherapeutic products. Unlike conventional probiotics, their next-generation probiotics can survive in inflamed guts. They’ve launched a food supplement capsule targeting IBS, showing significant symptom improvement in 80% of users after 8 weeks. The product is gluten and dairy-free and requires no refrigeration. The company seeks distributors with experience in consumer healthcare and food supplements through a commercial agreement.
- Full Description
-
The UK company is an R&D Company, formed in 2019 as a spin-out from a leading South West university, to take anti-inflammatory live biotherapeutic products into commercial production as food supplements or as prescribed therapeutics. Gastrointestinal inflammation is a key component of many diseases affecting millions of people worldwide. Despite its high prevalence, a lack of treatment options means patients are often reliant on drugs with negative side effects. Probiotics are popular due to their perception as safe, natural treatments, but currently marketed products cannot function during active disease or periods or stress.
The company develops next generation probiotics which can survive in the harsh environment of a stressed or actively inflamed gut and have anti-inflammatory properties. It has already launched a food supplement capsule containing its unique and patented lead strain of bacteria, targeted towards people with irritable bowel syndrome.
Trials of this product have demonstrated statistically significant improvements to common IBS symptoms such as loose stool, bloating, abdominal pain, cramping, flatulence, and constipation. 80% of users reported improvement to their symptoms after 8 weeks of taking this product.
The company is currently selling the food supplement online and it can also be offered to distributor partners in key markets to sell into wholesale and retail markets, such as pharmacy, para-pharmacy, drugstore, health food and grocery channels.
The directors have extensive experience in this area: the CEO and Co-Founder has a PhD in gastrointestinal immunology and 16 years’ research experience in gastrointestinal disease. This director has been responsible for the development of the new product since its early stages and has led its commercialisation over the last few years.
The CTO and Co-Founder is a senior lecturer in infectious disease at a leading South West university. This director has worked on gastrointestinal disease for 20 years, and his research expertise is in the dynamics of bacterial populations during disease and their interaction with the host. The chair of the company has over 30 years’ experience of drug development, due diligence and licensing in multinational and early biotech companies.
The UK company is seeking a commercial agreement with distributors. - Advantages and Innovations
-
- This product is the only probiotic on the market specifically designed for use during an active flare up of a gut disorder or during periods of stress. Conventional probiotics do not survive in this environment and therefore cannot be of benefit during these times.
- Trials have demonstrated that this product has a statistically significant beneficial impact on common irritable bowel syndrome symptoms, such as loose stool, bloating, abdominal pain, cramping, flatulence, and constipation. 80% of users reported improvement to their symptoms after 8 weeks of taking this product.
- The product is both gluten and dairy-free as both of these foodstuffs can exacerbate conditions such as irritable bowel syndrome.
- The capsules are a convenient, one per day formulation and can be taken at any time of day, with or without food. They do not require refrigeration so are easy to store and transport and have a long shelf life.
- The capsules are enteric-coated to ensure that the full dose reaches the large intestine intact where it is most needed. - Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR granted
- IPR notes
- The company holds granted patents in Europe and the United States with claims directed to the strain described and its ability to survive in a stressed or inflamed gut. Protection is provided for use as a food, food supplement, nutraceutical or therapeutic.
Partner Sought
- Expected Role of a Partner
-
- Distributors with expertise in the consumer healthcare, and/or the food supplement sectors.
- Ideally with established distribution networks into the wholesale and retail marketplace, such as pharmacy, para-pharmacy, drugstore, health food and grocery channels.
- Track record of launching new brands into markets will be preferable.
- Distributors can cover single or multiple geographical markets. - Type and Size of Partner
- Big company
- SME 11-49
- SME <=10
- SME 50 - 249
- Type of partnership
- Commercial agreement
Dissemination
- Market keywords
- 05007007 - Other medical/health related (not elsewhere classified)
- Targeted countries
- All countries